Skip to main content
Log in

Duration of Hormone Replacement Therapy, Breast Tumour Size and Grade in a Screening Programme

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

One of the primary adverse effects of long-term use of hormone replacement therapy (HRT) is a modest increase in the risk of breast cancer. Breast tumours that develop in women using HRT have been shown to have prognostically favourable histological features but it is unclear if this is the case for both short- and long-term use.

Methods. We evaluated the association between HRT use with tumour size and histologic grade in a cohort of women aged over 55 years (n = 2200) diagnosed with invasive breast cancer at subsequent screen in BreastScreen Victoria (BSV), Australia between 1993 and 2000. BSV biennially screens women aged over 40 years with the target age group 50–69 years. Multiple linear regression was used to examine predictors of log-transformed tumour size and multinomial logistic regression was used to evaluate associations of HRT with tumour grade.

Results. Short-term users of HRT (≤5 years), were approximately 50% less likely to develop poorly-differentiated breast tumours OR 0.48 95%CI (0.28–0.82) or node-positive tumours OR 0.57 95%CI (0.35–0.94) than non-users. Long-term users of HRT (≥5 years) were also less likely to develop poorly-differentiated tumours OR 0.36 95%CI (0.24–0.56) but were not more likely to be node-positive than women not on HRT. Duration of HRT use was not significantly associated with tumour size.

Conclusion. HRT use, regardless of duration, was associated with breast tumours that were better differentiated and not significantly larger than women not on HRT, although only short-term use was associated with fewer node-positive tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350: 1047–1059, 1997

    Google Scholar 

  2. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Jama 288: 321–333, 2002

  3. Kavanagh AM, Mitchell H, Giles GG: Hormone replacement therapy and accuracy of mammographic screening. Lancet 355: 270–274, 2000

    Google Scholar 

  4. Gajdos C, Tartter PI, Babinszki A: Breast cancer diagnosed during hormone replacement therapy. Obstet Gynecol 95: 513–518, 2000

    Google Scholar 

  5. Harding C, Knox WF, Faragher EB, Baildam A, Bundred NJ: Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit. Brit Med J 312: 1646–1647, 1996

    Google Scholar 

  6. Jones C, Ingram D, Mattes E, Hahnel R: The effect of hormone replacement therapy on prognostic indices in women with breast cancer. Med J Australia 161: 106–110, 1994

    Google Scholar 

  7. Tabar L, Fagerberg G, Chen HH, Duffy SW, Gad A: Tumour development, histology and grade of breast cancers: prognosis and progression. Int J Cancer 66: 413–419, 1996

    Google Scholar 

  8. Schairer C, Gail M, Byrne C, Rosenberg PS, Sturgeon SR, Brinton LA et al.: Estrogen replacement therapy and breast cancer survival in a large screening study. J Nat Cancer Inst 91: 264–270, 1999

    Google Scholar 

  9. Jernstrom H, Frenander J, Ferno M, Olsson H: Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Brit J Cancer 80: 1453–1458, 1999

    Google Scholar 

  10. Willis DB, Calle EE, Miracle-McMahill HL, Heath Jr CW: Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Cause Control 7: 449–457, 1996

    Google Scholar 

  11. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M et al.: Postmenopausal hormone therapy and mortality. New Engl J Med 336: 1769–1775, 1997

    Google Scholar 

  12. Chen C, Weiss NS, Newcomb P, Barlow WE, White E: Hormone replacement therapy in relation to breast cancer. Jama 287: 734–741, 2002

    Google Scholar 

  13. Banks E: Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review. J Med Screen 8: 29–34, 2001

    Google Scholar 

  14. Wang H, Bjurstam N, Bjorndal H, Braaten A, Eriksen L, Skaane P et al.: Interval cancers in the Norwegian breast cancer screening program: frequency, characteristics and use of HRT. Int J Cancer 94: 594–598, 2001

    Google Scholar 

  15. O'Connor IF, Shembekar MV, Shousha S: Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study. J Clin Pathol 51: 935–938, 1998

    Google Scholar 

  16. Holli K, Isola J, Cuzick J: Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 16: 3115–3120, 1998

    Google Scholar 

  17. Stallard S, Litherland JC, Cordiner CM, Dobson HM, GeorgeWD, Mallon EA et al.: Effect of hormone replacement therapy on the pathological stage of breast cancer: population based, cross sectional study. Brit Med J 320: 348–349, 2000

    Google Scholar 

  18. Magnusson C, Holmberg L, Norden T, Lindgren A, Persson I: Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Tr 38: 325–334, 1996

    Google Scholar 

  19. Bilimoria MM, Winchester DJ, Sener SF, Motykie G, Sehgal UL, Winchester DP: Estrogen replacement therapy and breast cancer: analysis of age of onset and tumor characteristics. Ann Surg Oncol 6: 200–207, 1999

    Google Scholar 

  20. Sacchini V, Zurrida S, Andreoni G, Luini A, Galimberti V, Veronesi P et al.: Pathologic and biological prognostic factors of breast cancers in short-and long-term hormone replacement therapy users. Ann Surg Oncol 9: 266–271, 2002

    Google Scholar 

  21. Shelley JM, Smith AM, Dudley E, Dennerstein L: Use of hormone replacement therapy by Melbourne women. Aust J Public Health 19: 387–392, 1995

    Google Scholar 

  22. Marr G, Morris K, Kavanagh A: National Protocol for Recording 1. Size, Nodal Status and Grade of Invasive Breast Cancer and 2. Carcinoma In Situ. The NHMRC National Breast Cancer Centre, Sydney, NSW, 1998

    Google Scholar 

  23. Kavanagh AM, Mitchell H, Farrugia H, Giles GG: Monitoring interval cancers in an Australian mammographic screening programme. J Med Screen 6: 139–143, 1999

    Google Scholar 

  24. Sturgeon SR, Schairer C, Brinton LA, Pearson T, Hoover RN: Evidence of a healthy estrogen user survivor effect. Epidemiology 6: 227–231, 1995

    Google Scholar 

  25. Ma L, Fishell E, Wright B, HannaW, Allan S, Boyd NF: Casecontrol study of factors associated with failure to detect breast cancer by mammography. J Nat Cancer Inst 84: 781–785, 1992

    Google Scholar 

  26. Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, Taplin SH et al.: Breast density as a predictor of mammographic detection: comparison of interval-and screen-detected cancers. J Nat Cancer Inst 92: 1081–1087, 2000

    Google Scholar 

  27. Sala E, Warren R, McCann J, Duffy S, Day N, Luben R: Mammographic parenchymal patterns and mode of detection: implications for the breast screening programme. J Med Screen 5: 207–212, 1998

    Google Scholar 

  28. Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA et al.: Breast tumor characteristics as predictors of mammographic detection: comparison of intervaland screen-detected cancers. J Nat Cancer Inst 91: 2020–2028, 1999

    Google Scholar 

  29. Esteve J, Seradour B, Jacquemier J, Remontet L: Does a better grade of tumour occurring in women under hormone replacement therapy compensate for their lower probability of detection by screening mammography. J Med Screen 9: 70–73, 2002

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gertig, D.M., Erbas, B., Fletcher, A. et al. Duration of Hormone Replacement Therapy, Breast Tumour Size and Grade in a Screening Programme. Breast Cancer Res Treat 80, 267–273 (2003). https://doi.org/10.1023/A:1024953926221

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1024953926221

Navigation